Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’
Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages over currently available monoclonal antibodies. Aspen Neuroscience also debuted on the Nasdaq as it prepares for a pivotal test of its Parkinson’s disease cell therapy.
It’s A TRAP! Employer Concerns for Tuition Reimbursement and Other Employee Repayment Agreements
For life science employers who offer these benefits should pay particular attention to new state laws and regulations to ensure continued compliance.
A Meaningful Signal on Palliative Care – But Not Yet a Benefit
CMS asked the right questions - the ones that will determine whether any future benefit actually reaches these patients.
What’s Driving the Rise of Consumer Diagnostics?
At MedCity INVEST Digital Health, experts from Jona, Labcorp and Evvy discussed the drivers of consumer diagnostics.
BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug
BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisition earlier this year.